Fresenius Biotech is dedicated to delivering innovative therapeutics to patients with serious illnesses that have a high degree of unmet need. A focal point of the company´s activities is the development of immunotherapeutic products based on innovative antibody technologies. A focused approach to research and development combined with international marketing experience enables Fresenius Biotech to efficiently bring targeted therapeutics to a global patient population.
Our core competencies:
- Preclinical research and clinical development
- Worldwide registration of biopharmaceuticals
- Innovative marketing for specialized indications
- Attaining market access for innovative products
Founded in 2003, Fresenius Biotech employs approximately 200 employees in Europe and the USA. Fresenius Biotech is a subsidiary of Fresenius SE.
To the homepage of Fresenius Biotech